_domenica-lorusso-md-phd-on-recurrent-ovarian-cancer-treatment-update.jpg "Domenica Lorusso, MD, PhD, on Recurrent Ovarian Cancer: Treatment Update from parp Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 1 min 66 sec
✓ Published: 23-Oct-2018
✓ Published: 23-Oct-2018
Description:
Domenica Lorusso, MD, PhD, of the Instituto Nazionale Dei Tumori, discusses the role of PARP inhibitors in ovarian cancer treatment and guideline recommendations.
Domenica Lorusso, MD, PhD, of the Instituto Nazionale Dei Tumori, discusses the role of PARP inhibitors in ovarian cancer treatment and guideline recommendations.
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_gu-connect-eks-incorporating-parp-inhibitors-into-prostate-cancer-clinical-practice.webp "GU CONNECT EKS Incorporating PARP inhibitors into prostate cancer clinical practice from parp")
⏲ 47 min 2 sec ✓ 17-Nov-2022
_development-and-clinical-indications-of-parp-inhibitors.webp "Dr O’Connor speaks with ecancer about the development and application of PARP inhibitors.nnHe describes his research in treatment tolerability and the overlap of efficacy with observed PARP trapping,nnFor more on PARP inhibitors, watch our interview with Dr Elisabetta Leo here.nnSign up to ecancer for free to receive tailored email alerts for more videos like this.nnhttps://ecancer.org/account/register.php")
_part-5-brca-1-2-mutations-and-prostate-cancer.webp "This series of animations investigates the use of PARP inhibitors for prostate cancer treatment and has been developed by Prof Phillip Cornford in association with ecancer.nnThe BRCA genes are an important part of the repair process for the daily onslaught of DNA damage, any faults can mean mistakes start to build up in the DNA, which increases the chances of the cell becoming cancerous. nnThis video explores the role of BRCA 1 and 2 genes in the HRR pathway and how it induces prostate cancer. A")
_southboro-lab-spinning-top.webp "South Side and Peterboro teachers have come together to create a video on how to make a spinning top. The Forces in Motion video is part of the family event during PARP month.")
_13-14-parp-fox-reads.webp "This video is about 13_14 PARP Fox reads")
_asco-2018-integrating-genomic-data-throughout-treatment-for-prostate-cancer.webp "Prof Kurt Miller (Benjamin Franklin Medical Centre, Berlin, Germany) and Prof Bertrand Tombal (Cliniques Universitaire Saint Luc, Belgium) share their thoughts on the genomic data and its implications for prostate cancer treatment presented from day 1 at ASCO. They emphasise that taking a detailed family history of any breast cancer, ovarian cancer as well as prostate cancers is a vital first step for new patients. nnGenetic counselling for ‘healthy’ family members needs to be considered alo")
⏲ 10 min 0 sec ✓ 03-Jun-2018
_which-different-parp-inhibitors-are-available.webp "This series of animations investigates the current role of PARP inhibitor use in prostate cancer, and what we might expect in the future and has been developed by Prof Phillip Cornford in association with ecancer.nnPARP inhibitors treat certain types of cancer by blocking the PARP enzymes in cells. These enzymes help repair DNA damage, so blocking them can prevent cancer cells from repairing.nnPARP inhibitors have so far demonstrated efficacy in ovarian, breast, pancreatic, peritoneal and metast")
_solo-1-olaparib-or-placebo-for-patients-with-newly-diagnosed-brca-mutated-advanced-ovarian-cancer.webp "Dr. Susana Banerjee spoke to ecancer about the findings of the SOLO1 trial presented at ESMO 2020.nnShe first talked about the rationale behind using a PARP inhibitor (olaparib), for maintenance treatment of patients with newly diagnosed ovarian cancer and BRCA mutation.nnDr Banerjee then went on to explain how the results of the treatment group were better than the placebo group and how the findings of this study can impact the current ovarian cancer treatment.nnSign up to ecancer for free to r")
⏲ 2 min 4 sec ✓ 20-Sep-2020
_gu-connect-eks-incorporating-parp-inhibitors-into-prostate-cancer-clinical-practice.jpg)
_development-and-clinical-indications-of-parp-inhibitors.jpg)
_part-5-brca-1-2-mutations-and-prostate-cancer.jpg)
_southboro-lab-spinning-top.jpg)
_13-14-parp-fox-reads.jpg)
_asco-2018-integrating-genomic-data-throughout-treatment-for-prostate-cancer.jpg)
_which-different-parp-inhibitors-are-available.jpg)
_solo-1-olaparib-or-placebo-for-patients-with-newly-diagnosed-brca-mutated-advanced-ovarian-cancer.jpg)
![[+]](/images/menu.gif){kind=small}